Pathway Genomics Launches First Hispanic Targeted Screening Panel for BRCA1/2-Related Hereditary Cancers - OmeCare

Pathway Genomics Launches First Hispanic Targeted Screening Panel for BRCA1/2-Related Hereditary Cancers

San Diego, CA – June 2, 2015 – Pathway Genomics Corporation, a data-driven global healthcare company and precision medicine clinical laboratory, announced today the launch of BRCATrue™ Hispanic (8-Site), a site-specific genetic testing panel consisting of 8 recurrent BRCA1 and BRCA2 pathogenic variants found in individuals of Mexican and Hispanic descent.

Click to Tweet

“The BRCATrue™ Hispanic (8-Site) test gives providers the option to test specific BRCA1 and BRCA2 pathogenic variants that are recurrent in the Mexican and Hispanic populations,” said Ardy Arianpour, Pathway Genomics’ Chief Commercial Officer. “This targeted testing provides a more cost-effective testing option for individuals in these populations, and will allow for quicker delivery of results to patients and their providers.”

Pathogenic variants in the BRCA1 and BRCA2 genes have been recognized as major contributors to hereditary breast and ovarian cancer since the mid-1990s. In a large study of breast cancer survivors under the age of 65, the prevalence of BRCA1 pathogenic variants in Hispanic women was found to be second only to that found in women of Ashkenazi Jewish descent.

“I am very excited that the BRCATrue™ Hispanic (8-Site) genetic test is out on the market. It will be a very useful test that could potentially help many patients obtain a better understanding about their cancer risk,” said Dr. Cesar Gonzalez, Director of OPCION Oncology in Monterrey, Mexico.

Recent studies have shown that several recurrent BRCA1 and BRCA2 pathogenic variants account for a large proportion of the total number of BRCA1 and BRCA2 pathogenic variants identified in individuals of Hispanic descent with ancestral origins in Mexico.

To learn more about BRCATrue™ Hispanic (8-Site), visit

About Pathway Genomics Corporation

Since its founding in 2008, Pathway Genomics has rapidly become a leader in the commercial healthcare industry. Pathway Genomics’ success lies in its commitment to deliver innovative healthcare solutions. The company’s program with IBM Watson is the first of its kind. The program is a smartphone app that merges artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness information based on the individual’s health history.

Based in San Diego, the company’s CLIA and CAP accredited clinical laboratory provides physicians and their patients in more than 40 different countries with actionable and accurate precision healthcare information to improve, or maintain, health and wellness. Pathway Genomics’ testing services cover a variety of conditions including cancer risk, cardiac health, inherited diseases, nutrition and exercise response, as well as drug response for specific medications including those used in pain management and mental health. For more about Pathway Genomics, visit or follow us on Twitter, LinkedIn and Facebook